Sunday, April 05, 2015
Flesh eating flys?
A man had more than 100 flesh-eating maggots removed from his nose which, left untreated, would have destroyed his face.
As the gruesome video below reveals, the wriggling creatures were buried deep in the 65-year-old’s sinuses.
The man, from Sao Paulo, Brazil, was suffering from nasal myasis – where the nose and sinuses become infested with the larvae of flies.
The following video is being taken down, pass it around!
Fact sheet N°375
Updated February 2015
There are 3 main forms of leishmaniases – visceral (often known as kala-azar and the most serious form of the disease), cutaneous (the most common), and mucocutaneous.
Leishmaniasis is caused by the protozoan Leishmania parasites which are transmitted by the bite of infected sandflies.
The disease affects some of the poorest people on the planet, and is associated with malnutrition, population displacement, poor housing, a weak immune system and lack of resources.
Leishmaniasis is linked to environmental changes such as deforestation, building of dams, irrigation schemes and urbanization.
An estimated 1.3 million new cases and 20 000 to 30 000 deaths occur annually.
Only a small fraction of those infected by Leishmania parasites will eventually develop the disease.
Leishmaniasis is caused by a protozoa parasite from over 20 Leishmania species and is transmitted to humans by the bite of infected female phlebotomine sandflies. Over 90 sandfly species are known to transmit Leishmania parasites. There are 3 main forms of the disease:
Visceral leishmaniasis (VL also known as kala-azar) is fatal if left untreated. It is characterized by irregular bouts of fever, weight loss, enlargement of the spleen and liver, and anaemia. It is highly endemic in the Indian subcontinent and in East Africa. An estimated 200 000 to 400 000 new cases of VL occur worldwide each year. Over 90% of new cases occur in 6 countries: Bangladesh, Brazil, Ethiopia, India, South Sudan and Sudan.
Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis and causes skin lesions, mainly ulcers, on exposed parts of the body, leaving life-long scars and serious disability. About 95% of CL cases occur in the Americas, the Mediterranean basin, the Middle East and Central Asia. Over two thirds of new CL cases occur in 6 countries: Afghanistan, Algeria, Brazil, Colombia, Iran (Islamic Republic of) and the Syrian Arab Republic. An estimated 0.7 million to 1.3 million new cases occur worldwide annually.
Mucocutaneous leishmaniasis leads to partial or total destruction of mucous membranes of the nose, mouth and throat. Almost 90% of mucocutaneous leishmaniasis cases occurs in the Plurinational State of Bolivia, Brazil and Peru.
Leishmania parasites are transmitted through the bites of infected female phlebotomine sandflies. The epidemiology of leishmaniasis depends on the characteristics of the parasite species, the local ecological characteristics of the transmission sites, current and past exposure of the human population to the parasite and human behaviour. Some 70 animal species, including humans, have been found as natural reservoir hosts of Leishmania parasites.
In the Mediterranean basin, visceral leishmaniasis is the main form of the disease. It occurs in rural areas, in villages in mountainous regions and also in some periurban areas, where Leishmania parasites live on dogs and other animals.
In South-East Asia, visceral leishmaniasis is the main form of the disease. Transmission generally occurs in rural areas below 600m above sea level, with a heavy annual rainfall, with a mean humidity above 70%, a temperature range of 15–38 °C, abundant vegetation, subsoil water and alluvial soil. The disease is most common in agricultural villages where houses are frequently constructed with mud walls and earthen floors, and cattle and other livestock live close to humans.
In East Africa, there are frequent outbreaks of visceral leishmaniasis in the northern acacia–balanite savanna and the southern savanna and forest areas where sandflies live around termite mounds. Cutaneous leishmaniasis occurs in the highlands of Ethiopia and other places in East Africa, where increased human–fly contact occurs in villages built on rock hills or river banks, which are the natural habitat of hyraxes.
In Afro-Eurasia, cutaneous leishmaniasis is the main form of the disease. Agricultural projects and irrigation schemes can increase the prevalence of cutaneous leishmaniasis as people who have no immunity to the disease move in to work on the projects. Large outbreaks in densely populated cities also occur, especially during war and large-scale population migration. The parasites causing cutaneous leishmaniasis live mainly on humans or rodents.
Kala-azar in the Americas is very similar to that found in the Mediterranean basin. The habit of keeping dogs and other domestic animals inside the house is thought to promote human infection. The epidemiology of CL in the Americas is complex, with variations in transmission cycles, reservoir hosts, sandfly vectors, clinical manifestations and response to therapy, and multiple circulating Leishmania species in the same geographical area.
Post-kala-azar dermal leishmaniasis (PKDL)
PKDL is a sequel of visceral leishmaniasis that appears as macular, papular or nodular rash usually on face, upper arms, trunks and other parts of the body. It occurs mainly in East Africa and on the Indian subcontinent, where up to 50% and 5–10% of patients with kala-azar, respectively, develop the condition. It usually appears 6 months to 1 or more years after kala-azar has apparently been cured, but can occur earlier. People with PKDL are considered to be a potential source of kala-azar infection.
Leishmania-HIV co-infected people have high chance of developing the full-blown clinical disease, and high relapse and mortality rates. Antiretroviral treatment reduces the development of the disease, delays relapses and increases the survival of the co-infected patients. High leishmania-HIV co-infection rates are reported from Brazil, Ethiopia and the state of Bihar in India.
Major risk factors
Poverty increases the risk for leishmaniasis. Poor housing and domestic sanitary conditions (e.g. lack of waste management, open sewerage) may increase sandfly breeding and resting sites, as well as their access to humans. Sandflies are attracted to crowded housing as these provide a good source of blood-meals. Human behaviour, such as sleeping outside or on the ground, may increase risk. The use of insecticide-treated bednets reduces risk.
Diets lacking protein-energy, iron, vitamin A and zinc increase the risk that an infection will progress to kala-azar.
Epidemics of both main forms of leishmaniasis are often associated with migration and the movement of non-immune people into areas with existing transmission cycles. Occupational exposure as well as widespread deforestation remain important factors. For example, people settling in areas that used to be forests may be moving near sandflies’ habitat. This can lead to a rapid increase in cases.
Environmental changes that can affect the incidence of leishmaniasis include urbanization, domestication of the transmission cycle and the incursion of agricultural farms and settlements into forested areas.
Leishmaniasis is climate-sensitive, and strongly affected by changes in rainfall, temperature and humidity. Global warming and land degradation together affect the epidemiology of leishmaniasis in a number of ways:
changes in temperature, rainfall and humidity can have strong effects on vectors and reservoir hosts by altering their distribution and influencing their survival and population sizes;
small fluctuations in temperature can have a profound effect on the developmental cycle of Leishmania promastigotes in sandflies, allowing transmission of the parasite in areas not previously endemic for the disease;
drought, famine and flood resulting from climate change can lead to massive displacement and migration of people to areas with transmission of leishmaniasis, and poor nutrition could compromise their immunity.
Diagnosis and treatment
In visceral leishmaniasis, diagnosis is made by combining clinical signs with parasitological, or serological tests (rapid diagnostic tests and others). In cutaneous and mucocutaneous leishmaniasis serological tests have limited value. In cutaneous leishmaniasis, clinical manifestation with parasitological tests confirms the diagnosis.
The treatment of leishmaniasis depends on several factors including type of disease, parasite species and geographic location. Leishmaniasis is a treatable and curable disease. All patients diagnosed as visceral leishmaniasis require prompt and complete treatment. Detailed information on treatment of the various forms of the disease by geographic location is available in the WHO technical report series 949 on the control of leishmaniasis.
Prevention and control
Prevention and control of leishmaniasis require a combination of intervention strategies because transmission occurs in a complex biological system involving the human host, parasite, sandfly vector and in some causes an animal reservoir host. Key strategies include:
Early diagnosis and effective case management reduces the prevalence of the disease and prevents disabilities and death. Currently there are highly effective and safe anti-leishmanial medicines particularly for VL and access to these medicines has significantly improved.
Vector control helps to reduce or interrupt transmission of disease by controlling sandflies, especially in domestic conditions. Control methods include insecticide spray, use of insecticide–treated nets, environmental management and personal protection.
Effective disease surveillance is important. Early detection and treatment of cases helps reduce transmission and helps monitor the spread and burden of disease.
Control of reservoir hosts is complex and should be tailored to the local situation.
Social mobilization and strengthening partnerships – mobilization and education of the community with effective behavioural change interventions with locally tailored communication strategies. Partnership and collaboration with various stakeholders and other vector-borne disease control programmes is critical.
WHO’s work on leishmaniasis control involves:
supporting national leishmaniasis control programmes;
raising awareness and advocacy on the global burden of leishmaniasis, and promoting equitable access to health services for disease prevention and case management;
developing evidence-based policy guidelines, strategies and standards for leishmaniasis prevention and control, and monitoring their implementation;
providing technical support to Member States to build sustainable, effective surveillance system and epidemic preparedness and response;
strengthening collaboration and coordination among partners, stakeholders and other bodies;
monitoring the global leishmaniasis situation, trends and measure progress in the disease control, and financing;
promoting research on effective leishmaniasis control including in the areas of safe, effective and affordable medicines, diagnostic tools and vaccines; facilitates the dissemination of research findings.